Home » FDA Reduces Follow-Up Requirement for Plantar Fasciitis Study
FDA Reduces Follow-Up Requirement for Plantar Fasciitis Study
FDA reduced the follow-up requirement from two years to one year for a Phase IIb study of injectable AmnioFix for the treatment of plantar fasciitis.
The approval of the protocol amendment was based on the injection’s safety profile and a lack of immunogenic response in study patients. Begun by MiMedx in August 2014, the trial involves up to 146 subjects at 20 clinical sites.
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May